Vioxx Gains Six Months Pediatric Exclusivity
This article was originally published in The Pink Sheet Daily
Merck gains six months of pediatric exclusivity for its COX-2 inhibitor Vioxx (rofecoxib) with a supplemental NDA filing for juvenile rheumatoid arthritis, the company announced Feb. 27
You may also be interested in...
FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.